Home > Newsletters > Devices & Diagnostics Letter > Communication Can Minimize Study Disruptions During IRB Transfers: FDA
Devices & Diagnostics Letter
June 18, 2012 | Vol. 39 No. 25
Communication Can Minimize Study Disruptions During IRB Transfers: FDA
To smoothly transition clinical investigation oversight from one institutional review board to another, devicemakers, contract research organizations (CRO), new and old IRBs and clinical investigators should work closely to minimize disruptions to the ongoing trial and ensure subjects are constantly protected, according to an FDA draft guidance.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.